Sucampo to be Added to the NASDAQ Biotechnology Index
BETHESDA, Md.--(BUSINESS WIRE)-- Sucampo Pharmaceuticals, Inc. (NAS: SCMP) (SPI) today announced that NASDAQ OMX Group, Inc. (NAS: NDAQ) will include the company in the NASDAQ Biotechnology Index® (NAS: NBI) effective prior to market open on Monday, May 20, 2013.
The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on The NASDAQ Stock Market that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB). The NASDAQ Biotechnology Index is a modified market capitalization weighted index. Among the various criteria that must be met in order to be eligible for inclusion in this index are a market capitalization of at least $200 million and an average daily trading volume of at least 100,000 shares. The NASDAQ Biotechnology Index is re-ranked semi-annually in May and November.
About Sucampo Pharmaceuticals, Inc.
Sucampo Pharmaceuticals, Inc. is a global pharmaceutical company focused on innovative research, discovery, development and commercialization of proprietary drugs based on prostones. The therapeutic potential of prostones was first discovered by Ryuji Ueno, M.D., Ph.D., Ph.D., Sucampo's Chairman, Chief Executive Officer, Chief Scientific Officer, and co-founder. Prostones, naturally occurring fatty acid metabolites that have emerged as promising compounds with unique physiological activities, can be targeted for the treatment of unmet or underserved medical needs. For more information, please visit www.sucampo.com.
AMITIZA is a registered trademark of Sucampo AG. The Sucampo logo and the tagline, The Science of Innovation, are registered trademarks of Sucampo AG.
Sucampo Pharmaceuticals, Inc.
Silvia Taylor, 1-240-223-3718
KEYWORDS: United States North America Maryland
The article Sucampo to be Added to the NASDAQ Biotechnology Index originally appeared on Fool.com.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.